Inclusion Criteria:

          -  Diagnosis of Philadelphia chromosome (Ph)-positive or BCR-ABL positive CML in early
             chronic phase CML (i.e., time from diagnosis is 12 months); except for hydroxyurea
             and/or 1 to 2 doses of cytarabine patients, patients must have received no or minimal
             prior therapy, defined as < 1 month (30 days) of prior Food and Drug Administration
             (FDA) approved tyrosine kinase inhibitor (TKI)

          -  Patients with clonal evolution and no other criteria for accelerated phase will be
             eligible for this study

          -  Eastern Cooperative Oncology Group (ECOG) performance of 0-2

          -  Total bilirubin < 1.5 x upper limit normal (ULN)

          -  Serum glutamate pyruvate transaminase (SGPT) < 3 x ULN

          -  Creatinine < 1.5 x ULN

          -  Patients must sign an informed consent indicating they are aware of the
             investigational nature of this study, in keeping with the policies of the hospital

        Exclusion Criteria:

          -  New York Heart Association (NYHA) cardiac class 3-4 heart disease

          -  Patients meeting the following criteria are not eligible unless cleared by cardiology:

               -  Uncontrolled angina within 3 months

               -  Diagnosed or suspected congenital long QT syndrome

               -  Any history of clinically significant ventricular arrhythmias (such as
                  ventricular tachycardia, ventricular fibrillation, or Torsades de pointes)

               -  Prolonged corrected QT (QTc) interval on pre-entry electrocardiogram (> 460 msec)

               -  History of significant bleeding disorder unrelated to cancer, including:

                    -  Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease)

                    -  Diagnosed acquired bleeding disorder within one year (e.g., acquired
                       anti-factor VIII antibodies)

          -  Patients with active, uncontrolled psychiatric disorders include: psychosis, major
             depression, and bipolar disorders

          -  Subject is known to be positive for human immunodeficiency virus (HIV); (HIV testing
             is not required)

          -  Evidence of other clinically significant uncontrolled condition(s) including, but not
             limited to:

               -  Uncontrolled and/or active systemic infection (viral, bacterial or fungal)

               -  Chronic hepatitis B virus (HBV) or hepatitis C (HCV) requiring treatment; Note:
                  subjects with serologic evidence of prior vaccination to HBV (i.e. hepatitis B
                  surface [HBs] antigen negative-, anti-HBs antibody positive and anti-hepatitis B
                  core [HBc] antibody negative) or positive anti-HBc antibody from intravenous
                  immunoglobulins (IVIG) may participate

          -  Women of pregnancy potential must practice an effective method of birth control during
             the course of the study, in a manner such that risk of failure is minimized; prior to
             study enrollment, women of childbearing potential (WOCBP) must be advised of the
             importance of avoiding pregnancy during trial participation and the potential risk
             factors for an unintentional pregnancy; postmenopausal women must be amenorrheic for
             at least 12 months to be considered of non-childbearing potential; women must continue
             birth control for the duration of the trial and at least 3 months after the last dose
             of study drug; pregnant or breast-feeding women are excluded; all WOCBP must have a
             negative pregnancy test prior to first receiving investigational product; if the
             pregnancy test is positive, the patient must not receive investigational product and
             must not be enrolled in the study

          -  Patients in late chronic phase (i.e., time from diagnosis to treatment > 12 months),
             accelerated or blast phase are excluded; the definitions of CML phases are as follows:

               -  Early chronic phase:

                    -  Time from diagnosis to therapy 12 months

                    -  Late chronic phase:

                         -  Time from diagnosis to therapy > 12 months

               -  Blastic phase:

                    -  Presence of 30% blasts or more in the peripheral blood or bone marrow

               -  Accelerated phase CML:

                    -  Presence of any of the following features:

                         -  Peripheral or marrow blasts 15% or more

                         -  Peripheral or marrow basophils 20% or more

                         -  Thrombocytopenia < 100 x 10^9/L unrelated to therapy

                         -  Documented extramedullary blastic disease outside liver or spleen